Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company's innovative research and development capabilities have been validated, with a comprehensive advancement in its metabolic pipeline [7][15] - The company has successfully authorized UBT251 to Novo Nordisk, indicating strong clinical potential and efficient overseas clinical progression [15][27] - The company is expected to achieve peak domestic sales of UBT251 for weight loss indications at 4.3 billion yuan by 2032 [18][19] Summary by Sections 1. Short-term Pressure on Main Business - In the first half of 2025, the company reported revenue of 7.519 billion yuan (+4.8% YoY) and net profit of 1.894 billion yuan (+27.02% YoY) [12] - The demand for antibiotics has impacted main business profits, but the negative effects are expected to diminish as high base effects are eliminated [12][14] 2. Comprehensive Innovative Pipeline Layout - UBT251 has been successfully authorized to Novo Nordisk, showcasing the company's validated R&D capabilities [15] - UBT48128, based on the structure of Eli Lilly's orforglipron, has shown significant weight loss potential in preclinical studies [24] - UBT37034 has received FDA approval for clinical trials, targeting the neuropeptide Y2 receptor, which is crucial for obesity treatment [27] 3. Earnings Forecast and Investment Rating - The company is projected to achieve revenues of 138.6 billion yuan, 150.0 billion yuan, and 162.6 billion yuan for 2025-2027, with YoY growth rates of 0.7%, 8.2%, and 8.4% respectively [31] - The net profit is expected to be 31.1 billion yuan, 31.0 billion yuan, and 33.8 billion yuan for the same period, with YoY growth rates of 17.0%, -0.3%, and 9.1% respectively [31] - The report maintains the "Buy" rating based on the successful R&D progress of UBT251 and the robust pipeline of UBT48128 and UBT37034 [31]

Investment Rating - The report suggests a positive outlook for the company, indicating that the current market capitalization of HKD 57 billion is significantly undervalued, recommending active attention to the stock [6]. Core Insights - The company presented excellent preliminary efficacy and safety data for IMM2510, a PD-L1xVEGF dual antibody, at the 2025 World Lung Cancer Conference, showing an objective response rate (ORR) of 35.3% and a progression-free survival (PFS) of 9.4 months in patients with advanced squamous non-small cell lung cancer (sq-NSCLC) [2][3]. - The safety profile of IMM2510 is manageable, with common grade ≥3 treatment-related adverse events (TRAEs) reported at 8.7% for thrombocytopenia, lymphopenia, and infusion-related reactions [3]. - The company has a rich pipeline with significant product potential, including the CD47CD20 dual antibody (IMM0306) and other candidates, indicating a broad space for business development [4][5]. Summary by Sections Clinical Data - The ORR for IMM2510 was reported at 35.3% (6 out of 17 patients), with a disease control rate (DCR) of 76.5% (13 out of 17). The median duration of response (DoR) was 7.59 months, and the median PFS was 9.4 months [2]. Safety Profile - Among 23 enrolled patients, the common grade ≥3 TRAEs included thrombocytopenia (8.7%), lymphopenia (8.7%), and infusion-related reactions (8.7%), indicating that the safety of IMM2510 is controllable [3]. Pipeline and Development - The company is advancing multiple clinical trials, including a Phase III registration trial for IMM2510 in sq-NSCLC and various combinations with other therapies [3]. The CD47 fusion protein (IMM01) is progressing well in Phase III trials for CMML and cHL, with mid-term data analysis expected next year [5]. Additionally, the new drug IMM72 for pulmonary arterial hypertension (PAH) has received approval and is currently recruiting healthy volunteers [5].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [11][13]. Core Viewpoints - The company is positioned as a leading third-party instant delivery platform in China, benefiting from the rapid growth of instant retail and the increasing demand for delivery services [4][11]. - The company's unique market positioning and service model have created a scarcity barrier in delivery capacity, which is expected to drive profitability as order volumes and rider efficiency improve [4][11]. Summary by Sections Company Overview - The company, Shunfeng Tongcheng, is the largest third-party instant delivery platform in China, providing a flexible delivery network for various consumer needs [8][18]. - The main business segments include delivery services for merchants (42% of revenue), personal errands (15%), and express collection and delivery services (42%) [8][18]. Instant Retail Growth - Instant retail is experiencing explosive growth, driven by a shift in consumer behavior towards convenience and immediate consumption [9][39]. - The market is expected to expand significantly, with projections indicating that the instant retail market could exceed 700 billion yuan by 2025 [52]. Delivery Infrastructure - Instant delivery serves as the foundational infrastructure for instant retail, with a focus on building a robust rider network to meet increasing order volumes [10][74]. - The company employs a "quasi-direct" management model for riders, ensuring high service quality and operational efficiency [10][74]. Financial Performance - The company achieved its first annual profit in 2023, with net profit expected to double to 1.3 billion yuan in 2024 [11][35]. - Revenue growth is driven by a compound annual growth rate (CAGR) of 24.4% from 2021 to 2024, with significant contributions from all business segments [35][36]. Market Positioning - The company maintains a neutral market position, allowing it to serve a wide range of clients without favoring specific channels [11][18]. - Strong collaboration with the parent company, Shunfeng Group, enhances operational efficiency and cost reduction in last-mile delivery [11][18].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 48.50, representing a potential upside of 15.0% from the current price of HKD 42.24 [2][4]. Core Insights - The company has solidified its leading position in the commercial management sector, with a significant increase in operational efficiency and a high dividend payout ratio [4]. - The commercial management segment reported a revenue increase of 14.6% year-on-year, with a gross margin improvement of 5.2 percentage points to 66.1% [4]. - The property management segment has seen a slight revenue growth of 1.1%, with urban space revenue increasing by 15.1% [4]. - The company has achieved a core net profit growth of 15.0% in the first half of 2025, with a total revenue of HKD 85.24 billion, reflecting a year-on-year increase of 6.5% [4]. Financial Summary - Revenue projections for the company are as follows: - 2023A: 14,766,952 thousand RMB - 2024A: 17,042,658 thousand RMB - 2025E: 18,326,302 thousand RMB - 2026E: 20,224,277 thousand RMB - 2027E: 22,407,889 thousand RMB - The growth rates are 22.9%, 15.4%, 7.5%, 10.4%, and 10.8% respectively [3][5]. - The projected net profit for the years 2025 to 2027 is as follows: - 2025E: 3,998,766 thousand RMB - 2026E: 4,596,336 thousand RMB - 2027E: 5,259,012 thousand RMB - The growth rates are 10.2%, 14.9%, and 14.4% respectively [3][5]. - The company plans to distribute a mid-term dividend of HKD 0.53 per share and a special dividend of HKD 0.35 per share, achieving a mid-term payout ratio of 100% based on core net profit [4].

证券研究报告 | 2025年09月10日 中创新航（03931.HK） 优于大市 动储电池市场份额稳步提升，盈利能力持续改善 资料来源：Wind、国信证券经济研究所预测 注：摊薄每股收益按最新总股本计算 核心观点 公司研究·海外公司财报点评 公司2025H1 实现归母净利润4.66 亿元、同比+87%。公司2025H1 实现营收164.19 亿元，同比+32%；实现净利润（含少数股东权益）7.53 亿元，同比+81%；实现 归母净利润 4.66 亿元，同比+87%；毛利率为 17.53%，同比+1.91pct；净利率为 4.59%，同比+1.24pct。 公司动力电池市场份额稳步提升，商用车市场开拓成果显著。2025H1 公司动力 电池业务实现营收 106.62 亿元，同比+10%；动力电池装车量 21.8GWh，同比+23%。 2025H1 公司在全球动力电池市场出货排名第四、国内动力电池市场出货排名第 三。乘用车市场，公司在国内市占率创新高，2025 年 7 月单月市占率达到 8.25%。 公司与大众、现代、丰田、奥迪、小鹏、零跑、长安等国内外头部企业深入合作， 交付产品类型日益丰富。商用车市场，公司 2 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 25.20, indicating a potential upside of 59.5% from the current price of HKD 15.80 [5]. Core Insights - The company has demonstrated strong performance with a revenue of RMB 1.569 billion in the first half of 2025, reflecting a year-on-year growth of 23.7%. Gross profit increased by approximately 27.6% to RMB 1.209 billion, with a gross margin of 77.1%, up 2.4 percentage points from the same period in 2024 [2]. - The core product, Uremic Clear Granules, continues to drive growth, achieving sales of approximately RMB 1.131 billion, a 28.0% increase compared to 2024. This product holds a leading position in the modern Chinese medicine category for kidney disease [3][4]. - The company has a robust dividend policy, proposing an interim dividend of HKD 0.33 per share, resulting in a payout ratio exceeding 51% [2]. Summary by Sections Financial Performance - For the fiscal year ending December 31, 2023, the company reported revenues of RMB 2.590 billion, with a projected increase to RMB 3.477 billion in 2025, representing a growth rate of 17.2% [6]. - Net profit is expected to rise from RMB 784.5 million in 2023 to RMB 1.052 billion in 2025, with diluted earnings per share increasing from RMB 0.98 to RMB 1.23 during the same period [6]. Product and Market Position - Uremic Clear Granules is the company's flagship product, uniquely positioned in the market with a significant competitive advantage. It is the first kidney disease Chinese medicine to complete evidence-based medical research and has received strong recommendations in clinical guidelines [4]. - The company has expanded its product pipeline, with several new imaging contrast agents launched and ongoing research products awaiting approval, enhancing its market offerings [3]. Strategic Outlook - The company is focused on optimizing its operational structure and deepening strategic layouts, which is expected to sustain its growth trajectory. The kidney disease product segment is anticipated to maintain stable sales growth due to its unique market position and the absence of significant competing products [4][5].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 17.27, representing a potential upside of 55% from the current price of HKD 11.14 [6][7]. Core Insights - The company's gaming business shows stable growth, with a focus on cost reduction and efficiency improvements, while the education segment faces short-term challenges due to budget constraints [3][7]. - The company has a solid financial position with net cash of approximately RMB 1.5 billion and digital asset reserves including 12,000 Ethereum [7]. - The gaming segment's revenue for the first half of 2025 is projected to be RMB 1.74 billion, down 18% year-on-year, but showing signs of stabilization with a slight quarter-on-quarter decline [7]. - The education business, particularly Mynd.ai, reported revenue of RMB 640 million, impacted by tightening customer budgets, but the long-term digitalization trend in education remains intact [7]. Summary by Sections Financial Performance - Total revenue for the fiscal year ending December 31, 2023, was RMB 7.1 billion, with a projected decline of 19.13% in 2025 [7][8]. - Adjusted net profit for 2025 is estimated at RMB 480 million, reflecting a significant recovery of 105.28% compared to the previous year [7][8]. - The company plans to distribute an interim dividend of HKD 0.5 per share and aims to return at least HKD 600 million to shareholders through dividends and share buybacks over the next year [7]. Business Segments Gaming Business - The gaming segment's revenue is expected to stabilize, with MAU for "Magic Domain" increasing by 11% year-on-year, indicating improved user engagement [7]. - New game launches and expansions into overseas markets are anticipated to drive future growth [7]. Education Business - The education segment is under pressure due to reduced budgets in traditional markets, but the company is exploring emerging markets for growth opportunities [7]. - The long-term outlook for digital education remains positive despite short-term fluctuations [7].

Investment Rating - The investment rating for the company is "Outperform the Market" [5][24]. Core Views - The company has shown a steady increase in market share in the power battery sector, with significant growth in commercial vehicle markets and a notable improvement in profitability [2][3]. - The company's revenue for the first half of 2025 reached 164.19 billion CNY, a year-on-year increase of 32%, while the net profit attributable to shareholders was 4.66 billion CNY, up 87% year-on-year [1][3]. - The company is ranked fourth globally and third domestically in power battery shipments, with a record market share of 8.25% in the passenger vehicle segment as of July 2025 [2][3]. Financial Performance - In the first half of 2025, the company achieved a gross margin of 17.53%, an increase of 1.91 percentage points year-on-year, and a net margin of 4.59%, up 1.24 percentage points year-on-year [1]. - The company's energy storage system products and other businesses generated revenue of 57.57 billion CNY in the first half of 2025, reflecting a 110% year-on-year growth [3]. - The forecasted net profit for the company from 2025 to 2027 is expected to be 13.76 billion CNY, 21.18 billion CNY, and 30.28 billion CNY, representing year-on-year growth rates of 133%, 54%, and 43% respectively [3][4]. Market Expansion and Strategic Partnerships - The company has established deep collaborations with leading domestic and international firms such as Volkswagen, Hyundai, Toyota, and others, enhancing its product offerings [2]. - The company is expanding its global footprint with new production bases in Thailand and Europe, which will improve its international delivery efficiency [3]. - Strategic partnerships with domestic clients like State Power Investment Corporation and China Nuclear Energy are being deepened to support rapid business growth [3].

Investment Rating - The investment rating for the company is "Outperform the Market" [6][49]. Core Views - The company achieved a revenue of 253 million yuan in H1 2025, representing a year-on-year growth of 40.4%. However, it reported a net loss of 762 million yuan, primarily due to fluctuations in the fair value of financial instruments issued to investors [1][7][21]. - The company is accelerating the mass production of its A1000 and C1200 chips, which are being integrated into various new vehicle models, enhancing its market presence in both domestic and international markets [2][22][30]. - The company is actively expanding its commercialization efforts in robotics, unmanned logistics vehicles, and intelligent imaging solutions, aiming to become a leader in the AI chip sector [3][36][48]. Financial Performance - In H1 2025, the company's gross margin was 24.79%, down 25.21 percentage points year-on-year, with a net margin of -301.47%, a decline of 914.76 percentage points year-on-year [2][15]. - The revenue from autonomous driving products and solutions was 237 million yuan, up 41.5% year-on-year, driven by increased sales of advanced driver-assistance systems [10][21]. - The company expects revenues of 810 million, 1.27 billion, and 2 billion yuan for 2025, 2026, and 2027 respectively, with projected net profits of -976 million, -678 million, and 740 million yuan [4][49]. Business Segments - The autonomous driving segment is seeing significant growth, with a focus on enhancing market penetration in commercial vehicles and expanding customer base [10][21]. - The intelligent imaging solutions segment generated 16 million yuan in revenue, reflecting a year-on-year increase of 24.8%, attributed to gaining market recognition [10][21]. - The company is also developing a range of AI solutions for robotics and logistics, leveraging its proprietary chips to enhance functionality and performance [36][48]. Market Position and Strategy - The company is positioned as a leading domestic supplier of intelligent automotive computing chips, benefiting from the accelerating penetration of smart driving technologies [49]. - The strategy includes deepening collaborations with major automotive manufacturers and expanding into overseas markets, which is expected to enhance revenue growth [21][49]. - The company plans to acquire high-performance, low-power AI chip firms to strengthen its product offerings and market position in the AI chip sector [48].

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of HKD 24.11 [2][10]. Core Insights - The company's net profit increased by 94% year-on-year, with significant improvements across various business segments [2][7]. - Return on Equity (ROE) rose to 3.6%, up by 1.5 percentage points year-on-year, indicating enhanced profitability [2]. - The company reported a total revenue of HKD 128 billion, a year-on-year increase of 44.1% [7]. Financial Performance Summary - **Return on Equity (ROE)**: 3.6%, up 1.5 percentage points year-on-year; quarterly ROE at 1.9%, up 1 percentage point year-on-year [2]. - **Net Profit Margin**: 33.8%, up 8.7 percentage points year-on-year; quarterly net profit margin at 32.3%, up 12.6 percentage points year-on-year [2]. - **Total Assets**: HKD 544.3 billion, an increase of HKD 608.9 billion year-on-year [8]. - **Net Assets**: HKD 118.8 billion, up HKD 131.5 billion year-on-year [8]. - **Leverage Ratio**: 4.58 times, stable compared to previous periods [2][8]. Business Segment Performance - **Proprietary Business Revenue**: HKD 72.5 billion, with a quarterly revenue of HKD 38.6 billion, showing a quarter-on-quarter increase [3]. - **Credit Business**: Interest income of HKD 39.9 billion, with a quarterly income of HKD 20 billion [3]. - **Brokerage Business Revenue**: HKD 26.5 billion, a year-on-year increase of 44.2% [9]. - **Investment Banking Revenue**: HKD 16.7 billion, with a significant increase in underwriting amounts for IPOs and refinancing [9]. Earnings Forecast - Expected Earnings Per Share (EPS) for 2025, 2026, and 2027 are projected at RMB 1.55, RMB 1.63, and RMB 1.77 respectively, with corresponding Price-to-Earnings (PE) ratios of 12.3, 11.6, and 10.7 [10][11].